Navigation Links
Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Date:11/12/2007

NEW ORLEANS, Nov. 12 /PRNewswire/ -- Two studies being presented at the American Academy of Ophthalmology's 2007 Annual Meeting suggest that telemedicine may have a significant role to play in the diagnosis of eye diseases, increased patient compliance and patient access to quality care.

In the first study, researchers examined the impact that telemedicine had on patients with diabetes being treated in multi-physician primary care practice. The study looked at the number of patients with diabetes over the course of a year who had the recommended retinal examination before the installation of a telemedicine remote imaging system in the practice versus the number of patients with diabetes who had a retinal examination in the two years following installation of the device.

"In the past, it has been shown that telemedicine is technically possible, but this study demonstrates the true impact of a telemedicine system on the number of patients with diabetes who end up having an evaluation for diabetic retinopathy," said Ingrid Zimmer-Galler, MD, assistant professor of ophthalmology at the Wilmer Eye Institute at the Johns Hopkins School of Medicine. "With this system, we've dramatically increased the rate of annual retinal evaluations."

In the first year, out of 1,257 diabetic patients in the study, only 15 percent had a retinal examination. Two years after implementation of the telemedicine system, 71 percent of the 1,395 diabetic patients in the practice had a retinal examination. Significantly, of the observed increase, 66 percent was due to an eye examination by a local ophthalmologist and only 33 percent was due to remote evaluation.

"It's very nice to see that increased rate of evaluations was not solely because these patients were undergoing remote imaging," said Dr. Zimmer- Galler. "It shows that by having this type of system in place, overall awareness of the problem increased and had a beneficial affect on all patients."

Incre
'/>"/>

SOURCE American Academy of Ophthalmology
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009).... 7 Patients reported C1-esterase ...rapy in treating acute swelling attacks at any bod...order, according to data presented today at the 20...ology (ACAAI) Annual Meeting. The results come fro...parallel with the ongoing, prospective, open label...
(Date:11/6/2009)... SCOLR Pharma, Inc. (Ame... three and nine months ended September 30, 2009. ... and CEO, said, "We continue to advance discussion...lation. Several potential partners have committed ...nal resources as they evaluate the potential comme...
(Date:11/6/2009)...ewswire-FirstCall/ -- Recession in domestic and in... Allied Healthcare Products in the first quarter o..., Sales declines pushed Allied into a loss for the...$745,000, or negative 9 cents per share, compared ..., or 3 cents per share. ,, Sales fell about 21...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 1Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 2Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 3Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 55567 4Fat Fighting Chemical Holds Promise 55564 1Fat Fighting Chemical Holds Promise 55564 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 1ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 3ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 4ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 5ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 6ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 7ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 8ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 9ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 10ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 11ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 13ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 14ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 15
...hKline (NYSE: GSK ),announced positive safety an...,controlled ITP Study with Eltrombopag), a Phase I...th chronic immune (idiopathic) thrombocytopenic,pu... therapies. Patients,receiving PROMACTA were eight...in platelet counts between 50,000 to 400,000/micro...
...he Local Treatment of Oral Candidiasis in Immunosu...J., Dec. 5 RHEI Pharmaceuticals, Inc. today annou... locally active antifungal with low dose miconazol...iated in China. This will be the last clinical tr...cation (NDA) to the State Food and Drug Administra...
Other Medicine Technology:GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2
(Date:11/9/2009)...t of seniors have changed Medicare plans, 16 perce...nd improved coverage among biggest drivers ,to cha... Belleville, Il (Vocus) No...have changed their Medicare plan since becoming el...ey are likely to or are considering switching plan...
(Date:11/9/2009)...for breast cancer are at higher risk of cancer rec...he December 15, 2009 issue of Cancer , a peer-rev...study,s results indicate that breast cancer patien...therapies following surgery, such as radiation. ,...breast tissue are at increased risk of breast canc...
(Date:11/8/2009)...USNewswire/ -- The American Public Health Associat...ovisions in the health reform bill passed last nig... the House takes important steps toward universal ...nd moving our health system from one that focuses ...g people healthy," said Georges C. Benjamin, MD, F...
(Date:11/8/2009)...ail Nation,s Job Creators ,, WASHINGTON, Nov. 8...use passage of the health care bill (H.R. 3962), S...Council) president & CEO Karen Kerrigan issued... those voting for H.R. 3962 voted to burden our na... taxes and penalties. Even in the best of economic...
(Date:11/8/2009)... of biopharmaceuticals to be available at the Comp... Toronto, ON (PRWEB) November ...erapure Biopharma Inc. today announced that the Co...rmaceutical grade freeze dryer and expects to make...vailable for contract manufacturing of biopharmace...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Breast density associated with increased risk of cancer recurrence 2Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
...tes call on Congress to pass meaningful health ref...on , , WASHINGTON, April 21 With millions of Am... insurance and health care, heart and stroke survi...th their representatives for the American Heart As...
...itute is pleased to welcome Tevi Troy, most recent...d Human Services (HHS) under George W. Bush, as a ...will write on health care, medical innovation, and...ining Hudson at this important juncture," says Hud...
... violence in urban communities show symptoms of po...l effects with a disruption to their normal cortis...ve long-term negative effects on their health. Acc...spital, Harvard Medical School in Boston, USA, bec...
..., , MONMOUTH JUNCTION, N.J., April 21 Transave, ...ent in a Phase II study evaluating the safety and ...inhalation) in non-cystic fibrosis (CF) bronchiect... Presently, there are no approved treatments for t...
...he latest series of wall-mounted diagnostic imagin... attractive covering , , NILES, Ill., April 21 M... images for more than three decades, introduces th...t created a new term when it became the industry,s...
...tronics, Inc. will enhance its Clinical Conductor(...rough integration to Interspond,s RxPaying(TM) deb...yment alternative which improves efficiency and in...ise can be integrated seamlessly. Dan Kerpelman, P...
Other Medicine News:Health News:Healthcare Reform Tops Agenda for Hundreds of Heart Disease and Stroke Survivors on Capitol Hill 2Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Witnessing violence affects kids' health 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 2Health News:Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study 3Health News:MAXANT Launches MediPort 3000, The Next-Generation of All-In-One Workstations, on Its Newly Designed Website 2Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2
Centrifuge 4-15C *Avaiable in Europe and Australia*
Centrifuge 4-15C *Available in Japan*
...khorse for the lab, featuring easy-to-use control ...ce. , Product features , , Digital display ... (W x D) footprint fits on a crowded bench, or in ...motor provides maintenance-free operation , Spi...
...Hz, 100/120 V Fast - Powerful g-Force for Fast a...s up to 14,000 rpm (18,000 x g) Ideal for pelleti... Fits on crowded bench or in a cold room Come...able fixed-angle rotor Quiet operation ≤ 58...
Medicine Products: